Vivo Capital’s Sinovac Biotech, Ltd SVA Stock Holding History

Vivo Capital’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.2M	Hold	5,903,000	–	–	3.49%	9
2026 Q1	$38.2M	Hold	5,903,000	–	–	3.17%	11
2025 Q4	$38.2M	Hold	5,903,000	–	–	2.47%	14
2025 Q3	$38.2M	Hold	5,903,000	–	–	3.07%	8
2025 Q2	$38.2M	Buy	+5,903,000	New	+$38.2M	3.91%	5
2024 Q4	–	Sell	-11,800,000	Closed	-$76.3M	–	46
2024 Q3	$76.3M	Hold	11,800,000	–	–	6.32%	5
2024 Q2	$76.3M	Hold	11,800,000	–	–	7.05%	4
2024 Q1	$76.3M	Buy	+11,800,000	New	+$76.3M	6%	4
2023 Q4	–	Sell	-5,900,000	Closed	-$38.2M	–	57
2023 Q3	$38.2M	Hold	5,900,000	–	–	4.18%	7
2023 Q2	$615M	Hold	5,900,000	–	–	42.47%	1
2023 Q1	$615M	Hold	5,900,000	–	–	42.7%	1
2022 Q4	$38.2M	Hold	5,900,000	–	–	4.4%	8
2022 Q3	$38.2M	Hold	5,900,000	–	–	4.21%	7
2022 Q2	$38.2M	Hold	5,900,000	–	–	3.83%	5
2022 Q1	$38.2M	Hold	5,900,000	–	–	2.63%	10
2021 Q4	$38.2M	Hold	5,900,000	–	–	2.3%	12
2021 Q3	$38.2M	Hold	5,900,000	–	–	1.71%	14
2021 Q2	$38.2M	Hold	5,900,000	–	–	1.65%	14
2021 Q1	$38.2M	Hold	5,900,000	–	–	1.34%	17
2020 Q4	$38.2M	Hold	5,900,000	–	–	1.7%	12
2020 Q3	$38.2M	Hold	5,900,000	–	–	2.21%	8
2020 Q2	$38.2M	Hold	5,900,000	–	–	2.74%	9
2020 Q1	$38.2M	Buy	+5,900,000	New	+$38.2M	3.46%	7
2019 Q3	–	Sell	-5,900,000	Closed	-$38.2M	–	51
2019 Q2	$38.2M	Hold	5,900,000	–	–	3.58%	8
2019 Q1	$38.2M	Hold	5,900,000	–	–	3.81%	6
2018 Q4	$40.9M	Hold	5,900,000	–	–	5.23%	5
2018 Q3	$45M	Buy	+5,900,000	New	+$42.6M	4.53%	5

Other funds holding SVA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Vivo Capital's SVA Position: Q2 2026 in Review

Vivo Capital held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 5,903,000 shares worth $38.2M. The position accounts for 3.49% of the portfolio, ranked #9.

Vivo Capital first reported a position in SVA in Q3 2018 and has held it in 27 quarters since. The position peaked at $615M in Q2 2023. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

Vivo Capital held 5,903,000 shares of Sinovac Biotech, Ltd worth $38.2M as of Q2 2026.
Vivo Capital left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
Sinovac Biotech, Ltd made up 3.49% of Vivo Capital's portfolio in Q2 2026, its #9 holding.
Vivo Capital first reported a position in Sinovac Biotech, Ltd in Q3 2018 and has held it in 27 quarters since.
Vivo Capital's Sinovac Biotech, Ltd position peaked at $615M in Q2 2023.
29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.